Physician profile
Kirk A Wilcox
NPI 1831222835
$14,298.82
in general payments reported to CMS, 2019-2025
53 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 95% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $1,528 · 2021: $1,842 · 2022: $2,130 · 2023: $2,297 · 2024: $2,481 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,024.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,178.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,526.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,290.37 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,051.92 | 2019-2025 | |
| Lilly USA, LLC | $1,028.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $922.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $844.46 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $701.37 | 2021-2025 | |
| Abbott Laboratories | $478.81 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $376.28 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $336.59 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Astellas Pharma US INC | $314.29 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $294.74 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $269.52 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $217.05 | 2019-2025 | Spravato |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.